Assessment of Serum High Mobility Group Box - 1 Level as Predictor of Diabetic Peripheral Neuropathy

Abstract

Background: High mobility group B1 is linked to central ischemia damage, and after an ischemic insult, it is discharged to the extracellular space, so that it stimulates neuroinflammation, such as neuropathy, which considered as a serious complication of diabetes that is challenging to heal. Objective: is to investigate the changes of sera levels of High Mobility.Group Box-1 Protein. (HMGB-1) as well as its connection with the incidence of developing neuropathic complications among diabetic patients. Material & Methods: A 30 patients with diabetic peripheral neuropathy was included with another 30 patients with Diabetes Mellitus type 2 without complications and a 30 healthy subject as control group both sex-aged matched with the patients groups. This study included the measurement of serum high.mobility group box-1. (HMGB-1) by ELISA technique in addition to HbA1c by turbidimetric immunoassay technology, Fasting blood sugar and finally Lipid.profile (Total cholesterol,. LDL, VLDL,. HDL and. Triglycerides) were measured by spectrophotometer. Results: Analyzing the current data of samples (n=90) showed that the comparison between serum level of HMGB-1 was significant. The mean of HMGB_1 for NPDM (689.08± 104.63) was significantly higher than both for Non-NPDM (354.97±137.56), p<0.001 and for control (312.91±100.66), (p<0.001). Also serum levels of (Total Cholesterol, TG, LDL, VLDL) of NPDM patients were significantly higher (p<0.001) than both Non-NPDM and control groups. We conclude that serum level of HMGB-1 can be used as predictor marker of neuropathy complication of type 2 diabetes.